Last updated on October 2018

Safety Tolerability and Efficacy of IONIS-GHR-LRx in up to 42 Adult Patients With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands

Brief description of study

The purpose is to assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in up to 42 Patients with Acromegaly

Detailed Study Description

This short-term study will assess changes in serum insulin-like growth factor 1 (IGF-1) over a 16-week treatment period in a patient population diagnosed with Acromegaly being treated with Long-acting Somatostatin Receptor Ligands (SRL)

Clinical Study Identifier: NCT03548415

Contact Investigators or Research Sites near you

Start Over

Ionis Pharmaceuticals

Spitalul Clinic Judetean Mures
Targu-Mures, Romania
  Connect »